Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2026-02-20 @ 1:43 PM
Study NCT ID:
NCT03319459
Status:
COMPLETED
Last Update Posted:
2021-11-22
First Post:
2017-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Sponsor:
Fate Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HER2 Positive Gastric Cancer | View |
| None | Colorectal Cancer | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | EGFR Positive Solid Tumor | View |
| None | Advanced Solid Tumors | View |
| None | HER2-positive Breast Cancer | View |
| None | Hepatocellular Carcinoma | View |
| None | Non Small Cell Lung Cancer | View |
| None | Renal Cell Carcinoma | View |
| None | Pancreatic Cancer | View |
| None | Melanoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Solid Tumor | View |
| None | HER2 | View |
| None | EGFR | View |
| None | Advanced Solid Tumor | View |
| None | Breast Cancer | View |
| None | Head and Neck Cancer | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Colorectal Cancer | View |
| None | Gastric Cancer | View |
| None | HER2 Positive | View |
| None | EGFR Positive | View |
| None | EGFR+ | View |
| None | HER2+ | View |
| None | Immunotherapy | View |
| None | NK cell therapy | View |
| None | Natural killer cell therapy | View |
| None | antibody-dependent cell-mediated cytotoxicity | View |
| None | ADCC | View |
| None | Non small cell lung cancer | View |
| None | Renal cancer | View |